Lademarco M F, Binkin N J, Tung L B, Quy H T, Cĵ N V
Pham Ngoc Thach Tuberculosis and Lung Diseases Center, Ho Chi Minh City, Vietnam.
Int J Tuberc Lung Dis. 2001 Jun;5(6):575-8.
Few data address the outcomes of patients who have multidrug-resistant tuberculosis (MDR-TB), defined as resistance to at least isoniazid and rifampin, and who receive a standard World Health Organization (WHO) recommended retreatment regimen after relapse or failure with initial treatment. In this case series, we examined treatment outcomes of a convenience sample of 42 relapse or failure patients who had documented MDR-TB and who had received a standard WHO retreatment regimen (2SHRZE/1HRZE/5H3R3E3). One patient died of tuberculosis in the last month of treatment; the remaining 41 patients completed retreatment. Of the 42, 14 (33%) were sputum smear-negative on completion of therapy. The proportion of patients cured of MDR-TB with the WHO retreatment regimen was similar to historic outcomes when no chemotherapy for TB was given.
很少有数据涉及耐多药结核病（MDR-TB，定义为至少对异烟肼和利福平耐药）患者在初次治疗复发或失败后接受世界卫生组织（WHO）推荐的标准复治方案后的治疗结果。在这个病例系列中，我们研究了42例有记录的耐多药结核病复发或失败患者的便利样本的治疗结果，这些患者接受了WHO标准复治方案（2SHRZE/1HRZE/5H3R3E3）。1例患者在治疗的最后一个月死于结核病；其余41例患者完成了复治。在这42例患者中，14例（33%）在治疗结束时痰涂片阴性。采用WHO复治方案治愈耐多药结核病的患者比例与未进行结核病化疗时的历史结果相似。
